ImpriMed’s CEO & Co-Founder, Dr. Sungwon Lim, will present a showcase session titled “Connecting the Right Drug to the Right Patient” on March 6 at 1:00 PM (Track S2). The session will highlight how our xCellSense™ platform combines ex vivo drug sensitivity testing on patients’ live cancer cells with AI-driven response prediction to support more informed therapy selection. Dr. Lim will also discuss how ImpriMed partners with pharmaceutical companies through CRO collaborations using real patient-derived samples to help de-risk drug development.
Click here to go to the official event page →ImpriMed’s CEO & Co-Founder, Dr. Sungwon Lim, will present a showcase session titled “Connecting the Right Drug to the Right Patient” on March 6 at 1:00 PM (Track S2). The session will highlight how our xCellSense™ platform combines ex vivo drug sensitivity testing on patients’ live cancer cells with AI-driven response prediction to support more informed therapy selection. Dr. Lim will also discuss how ImpriMed partners with pharmaceutical companies through CRO collaborations using real patient-derived samples to help de-risk drug development.
